Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBIT: 2020-2025

Historic EBIT for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Sep 2025 value amounting to -$41.0 million.

  • Maravai Lifesciences Holdings' EBIT rose 75.22% to -$41.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$194.2 million, marking a year-over-year increase of 5.31%. This contributed to the annual value of -$235.6 million for FY2024, which is 644.49% down from last year.
  • Per Maravai Lifesciences Holdings' latest filing, its EBIT stood at -$41.0 million for Q3 2025, which was up 38.09% from -$66.3 million recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBIT peaked at $180.7 million during Q2 2022, and registered a low of -$165.6 million during Q3 2024.
  • In the last 3 years, Maravai Lifesciences Holdings' EBIT had a median value of -$18.9 million in 2024 and averaged -$38.5 million.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' EBIT soared by 1,790.83% in 2021 and then plummeted by 974.23% in 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBIT (Quarterly) stood at $154.5 million in 2021, then fell by 29.31% to $109.2 million in 2022, then plummeted by 106.54% to -$7.2 million in 2023, then plummeted by 427.30% to -$37.7 million in 2024, then skyrocketed by 75.22% to -$41.0 million in 2025.
  • Its EBIT was -$41.0 million in Q3 2025, compared to -$66.3 million in Q2 2025 and -$49.2 million in Q1 2025.